Oculis Eyes Year-End Data for Licaminlimab as It Expands Neuro-Ophthalmology Push
Event summary
- Oculis to present Licaminlimab data at Eyecelerator @ AAO 2026 on October 8
- PREDICT-1 registrational trial for TNFR1-mediated dry eye disease on track for year-end topline readout
- Company sponsoring Neuro-Ophthalmology Subspecialty Day at AAO 2026
- Privosegtor in PIONEER program for optic neuritis and other neuro-ophthalmic diseases
The big picture
Oculis is doubling down on its neuro-ophthalmology focus with high-stakes clinical readouts approaching. The company's dual-pronged strategy targets both inflammatory dry eye disease with Licaminlimab and neuroprotective applications with Privosegtor, positioning itself at the intersection of precision medicine and unmet needs in ophthalmology. Success in either program could validate Oculis' approach to developing highly differentiated therapies for niche but significant patient populations.
What we're watching
- Clinical Validation
- Whether Licaminlimab's genotype-based approach will show statistically significant results in PREDICT-1 trial
- Regulatory Pathway
- The pace at which Privosegtor advances through PIONEER program with Breakthrough Therapy designation
- Market Differentiation
- How Oculis positions both candidates against existing treatments in competitive ophthalmology space